Patient characteristics
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 43 (21-65) |
| Sex (M/F), n (%) | 23/6 (79/21) |
| Diagnosis, n (%) | |
| Hodgkin disease | 14 (48) |
| Myeloma | 6 (21) |
| AML | 2 (6) |
| CML | 2 (6) |
| CLL | 2 (6) |
| NHL | 1 (3) |
| Breast cancer | 1 (3) |
| Renal cell cancer | 1 (3) |
| Donor, n (%) | |
| HLA-identical | 19 (65) |
| Matched unrelated | 10 (35) |
| Preparative regimen, n (%) | |
| Myeloablative | 6 (21) |
| Reduced intensity | 23 (79) |
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 43 (21-65) |
| Sex (M/F), n (%) | 23/6 (79/21) |
| Diagnosis, n (%) | |
| Hodgkin disease | 14 (48) |
| Myeloma | 6 (21) |
| AML | 2 (6) |
| CML | 2 (6) |
| CLL | 2 (6) |
| NHL | 1 (3) |
| Breast cancer | 1 (3) |
| Renal cell cancer | 1 (3) |
| Donor, n (%) | |
| HLA-identical | 19 (65) |
| Matched unrelated | 10 (35) |
| Preparative regimen, n (%) | |
| Myeloablative | 6 (21) |
| Reduced intensity | 23 (79) |